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ABSTRACT
 Objective: Giant parathyroid adenomas (GPAs) are a 
rare type of parathyroid adenoma (PA) weighing >2 to 3 g. 
The objective of this manuscript is to report a case of giant 
parathyroid adenoma and highlight the risk of postopera-
tive hypocalcemia.
 Methods: We describe the presentation and work-up 
of a woman with GPA confirmed with histopathology as 
well as management of postoperative hypocalcemia. 
 Results: A 66-year-old Caucasian female with chronic 
fatigue was found to have elevated calcium levels at 13.7 
mg/dL (normal, 8.9 to 10.2 mg/dL) and elevated parathy-
roid hormone levels at 1,240 pg/mL (normal, 12 to 72 pg/
mL). Contrast enhanced computed tomography scan of 
the neck showed a 5.6 cm heterogeneous mass posterior 
to the right thyroid. The patient underwent right parathy-
roidectomy and histopathology confirmed the diagno-
sis of a giant parathyroid adenoma (GPA) weighing 28.7 
g. Postoperatively, the patient developed hypocalcemia 
secondary to hungry bone syndrome and was treated 
aggressively with intravenous calcium supplementation. 
At 4 weeks postoperatively, she had normal calcium levels 
without any calcium supplementation.
 Conclusion: GPAs are a rare variant of PA, and could 
be a distinct clinical entity with features different from 
both PA and parathyroid carcinoma. We further postulate 
that the risk of postoperative hypocalcemia secondary to 
hungry bone syndrome could be higher among patients 
with GPA compared to patients with PA. These hypotheses 
needs to be validated with further studies. (AACE Clinical 
Case Rep. 2020;6:e352-e356)
Abbreviations:
CT = computed tomography; GPA = giant parathyroid 
adenoma; HBS = hungry bone syndrome; PA = para-
thyroid adenoma; PTH = parathyroid hormone
INTRODUCTION
 The normal parathyroid gland weighs about 50 to 
70 mg. Primary hyperparathyroidism is a common endo-
crine disorder and is one of the most frequent causes of 
hypercalcemia. Primary hyperparathyroidism is caused 
by a single parathyroid adenoma (85 to 90%), multigland 
disease (10%), and extremely rarely can be due to parathy-
roid carcinoma (1). Parathyroid adenoma leading to prima-
ry hyperparathyroidism extensively varies in size, and 
adenomas weighing >2 to 3 g are classified as “giant para-
thyroid adenomas” (2). The largest parathyroid adenoma 
reported in the literature weighed 110 g. Giant parathyroid 
adenomas (GPAs) are rare, and in limited studies including 
case reports and case series have been described to repre-
sent a different clinical entity. We report a case of giant 
parathyroid adenoma presenting with fatigue, polyuria, 
polydipsia, anorexia, and constipation secondary to long-
standing hypercalcemia, who developed post parathyroid-
ectomy symptomatic hypocalcemia requiring prolonged 
hospitalization.
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 A 66-year-old Caucasian female presented with a 
chief complaint of gradually progressive fatigue for 4 
weeks. The review of systems was positive for polyuria, 
polydipsia, anorexia, and constipation, but no weight loss, 
fevers, night sweats, dysphonia, dysphagia, recent nephro-
lithiasis, or osteoporotic fractures. Her past medical history 
was significant for a remote history of kidney stones about 
20 years before her presentation; however, she had not 
seen a physician for a prolonged period before her current 
visit to the hospital. She was not on any medication, and 
her family history was negative for any known calcium 
disorders or renal stone. She was tachycardic (103 beats 
per minute) with normal blood pressure (128/71 mm Hg) 
and temperature (98.2 °F) on presentation. Her body mass 
index was 24.3 kg/m2. The thyroid gland was unremark-
able without any nodule or lymphadenopathy. Laboratory 
workup (Table 1) showed elevated total calcium 13.7 mg/
dL (normal, 8.9 to 10.2 mg/dL) and significantly elevated 
intact parathyroid hormone (PTH) levels 1,240 pg/mL 
(normal, 12 to 72 pg/mL). Contrast-enhanced computed 
tomography (CT) of the neck revealed a heterogeneous 5.6 
cm soft tissue mass posterior to the right thyroid lobe in 
the tracheoesophageal groove, extending into the medias-
tinum (Fig. 1 A and B). A CT of the chest, abdomen, and 
pelvis again showed a 5.6 cm heterogeneous mass in the 
neck, along with multiple calcified mediastinal and hilar 
lymph nodes, calcifications in the pancreatic head, and 
bilateral nonobstructing renal calculi. She was diagnosed 
with PTH-induced hypercalcemia and the differential diag-
nosis included parathyroid adenoma or parathyroid carci-
noma. She was treated aggressively with intravenous fluids 
and electrolyte replacement, and in the first 24 hours, total 
calcium levels improved to 10.6 mg/dL. However, 48 hours 
from presentation, total calcium levels again increased to 
14.6 mg/dL, and she was given a dose of intravenous pami-
dronate 60 mg, following which her calcium levels normal-
ized. On the fifth day of hospitalization, the patient under-
went a right inferior parathyroidectomy. Histopathology 
confirmed the diagnosis of a giant parathyroid adenoma 
measuring 5.2 cm × 3.1 cm × 1.4 cm in size and weigh-
ing 28.7 g (Fig. 2). On postoperative day 0, she developed 
symptomatic hypocalcemia (total calcium of 8.8 mg/dL). 
She was started on aggressive calcium replacement with 
intravenous calcium gluconate. On postoperative day 7, 
she was discharged on calcitriol 0.5 µg 2 capsules orally 2 
times a day, calcium carbonate 500 mg (200 mg elemental 
calcium) 5 tablets orally 2 times a day, and ergocalciferol 
50,000 units orally once a week. The trend of calcium level 
is shown in Figure 3. At 3 weeks following the parathyroid-
ectomy, total calcium was 12 mg/dL, intact PTH was <10 
pg/mL and 25-hydroxyvitamin D was 20.6 ng/mL (normal, 
20 to 80 ng/mL). Hence, calcitriol and calcium carbonate 
was stopped. Calcium levels became normal (9.8 mg/dL) 1 
week later. At 6 weeks, laboratory work-up showed a total 
calcium of 9.4 mg/dL, an intact PTH of 72 pg/mL, a phos-
phorus level of 3.6 mg/dL (normal, 2.5 to 4.5 mg/dL), a 
serum creatinine of 1.77 mg/dL (normal, 0.60 to 1.10 mg/
dL), and an estimated glomerular filtration rate of 30 mL/
min/ 1.73 m2, suggesting secondary hyperparathyroidism 
in the presence of chronic kidney disease.
DISCUSSION
 Giant parathyroid adenomas are defined as parathyroid 
adenomas >3.5 g (3). GPAs are rare, and their true inci-
dence is unknown. A recent literature review by Al-Hassan 
et al (4) revealed only 22 cases of GPA between 2009 
to 2019.
 Clinical presentation of giant parathyroid adenoma is 
mostly similar to parathyroid adenoma. However, while 
parathyroid adenomas (PAs) is usually asymptomatic, GPA 
is mostly symptomatic (4,5). The classic constellation of 
symptoms is rarely seen these days due to frequent routine 
chemical assessment and timely intervention. However, 
our patient did not have a routine health check-up for a 
prolonged period and presented with symptoms suggestive 
of chronic hypercalcemia. Rarely, patients can present with 
severe conditions such as hyperparathyroidism crisis and 
acute pancreatitis (6,7). GPAs slowly grow over the years; 
however, occasionally, they can have rapid enlargement 
due to cystic changes (8).
 While both GPA and parathyroid carcinoma are rare 
entities, parathyroid carcinoma should always be suspect-
ed among patients with marked hypercalcemia, extremely 
high PTH levels, and a neck mass. GPA cannot be reli-
ably differentiated from parathyroid carcinoma based on 
localization imaging studies; however, local capsular or 
extracapsular invasion and/or distant metastasis are highly 
suggestive of parathyroid cancer (9). Invasion beyond the 
capsule appears to best correlate with the diagnosis of para-
thyroid cancer (10). Several studies have suggested GPAs 
to represent a distinct clinical entity compared to PAs with 
specific genomic aberrations such as mutations in parafi-
bromin, hyperparathyroidism 2 with jaw tumors (HRPT2; 
CDC73), multiple endocrine neoplasia type 1 (MEN1) and 
adenomatosis polyposis coli (APC) genes (3,11). Mutation 
of the HRPT2 (also called CDC73) tumor suppressor gene 
plays a significant role in the pathogenesis of parathyroid 
carcinoma and its presence has been found in hyperpara-
thyroidism-jaw tumor syndrome, sporadic parathyroid 
carcinoma, and isolated familial hyperparathyroidism (12). 
It is also noteworthy that some studies have proposed that 
previously resected parathyroid lesions could have been 
parathyroid carcinoma (13). Besides, head and neck radia-
tion can predispose to future risk of parathyroid carcinoma 
decades later (14).
 Compared to PAs, GPAs have a higher occurrence in 
males, is mostly a single gland disease (11), and has high-
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Table 1
Laboratory Results on Admission
Laboratory test Level Reference range
WBCs 10.07 K/uL 3.7-10.3 K/uL
RBCs 3.83 M/uL 3.-5.2 M/uL
Hemoglobin 11.4 g/dL 11.2-15.7 g/dL
Hematocrit 34.1% 34-45 %
Platelets 313 K/uL 155-369 K/uL
Plasma glucose 93 mg/dL 74-90 mg/dL
Serum sodium 139 mmol/L 136-145 mmol/L
Serum potassium 2.9 mmol/L 3.7-4.8 mmol/L
Serum bicarbonate 22 mmol/L 22-29 mmol/L
Serum chloride 105 mmol/L 97-107 mmol/L
Serum calcium, total 13.7 mg/dL 8.9-10.2 mg/dL
Ionized calcium 7.5 mg/dL 4.6-5.1 mg/dL
Serum magnesium 1.8 mg/dL 1.9-2.4 mg/dL
Serum phosphorus 2.7 mg/dL 2.5-4.5 mg/dL
Serum albumin 3.6 g/dL 3.3-4.6 g/dL
Blood urea nitrogen 19 mg/dL 0-30 ng/dL
Serum creatinine 1.95 mg/dL 0.60-1.10 mg/dL
Estimated GFR 26 mL/min/1.73 m2 >60 mL/min/1.73 m2
Serum aspartate transaminases 23 U/L 9-36 U/L
Serum alanine transaminases 37 U/L 8-33 U/L
Serum alkaline Phosphatase 243 U/L 46-142 U/L
Serum total protein 7.5 g/dL 6.3-7.9 g/dL
Serum lipase 159 U/L 19-63 U/L
Intact parathyroid hormone 1,240 pg/mL 12-72 pg/mL
Parathyroid hormone–related peptide 1.0 pmol/L ≤4.2 pmol/L
Vitamin D, 25 hydroxy 8.5 ng/mL 20-80 ng/mL
Vitamin 1,25 dihydroxy, total 20.3 pg/mL 20 to 45 pg/mL
Thyroid-stimulating hormone 0.87 uIU/mL 0.4-4.5 uIU/mL
Free T4 1.0 ng/dL 0.8-1.8 ng/dL
Random urine calcium 12.6 mg/dL
Random urine creatinine 17 mg/dL
Abbreviations: GFR = glomerular filtration rate; RBC = red blood cell; T4 = thyroxine; WBC = 
white blood cell.
er mean preoperative PTH and serum calcium levels (3). 
A retrospective review of parathyroidectomies between 
1996-2006 showed a positive correlation between the 
size of PA and preoperative PTH (15). The role of fine 
needle aspiration cytology is limited as it lacks the abil-
ity to differentiate between different types of parathyroid 
disease (16). 
 Localization of GPA is done following biochemical 
diagnosis and is most commonly done with a neck ultra-
sound and 99mTc-sestamibi scintigraphy (MIBI) scan. 
Neck ultrasound has a limitation to detect GPA if it is ecto-
pic or extends into the mediastinum, and therefore has a 
lower accuracy to predict the size (79%), which increases 
to 82% when it is combined with MIBI, and CT (3). In our 
patient, preoperative localization was done with contrast 
enhanced CT scan of neck. 
 Based on current guidelines for management of PA, 
our patient met indications to undergo parathyroidectomy 
(17). Postoperatively, patients with GPA are more likely 
to develop postoperative hypocalcemia (18). Our patient 
Hypocalcemia After Surgery for GPA, AACE Clinical Case Rep. 2020;6(No. 6)  e355 Copyright © 2020 AACE
Fig. 1. Contrast-enhanced computed tomography of the neck showing a heterogeneous soft tissue mass at the right 
tracheoesophageal groove, posterior to the right thyroid lobe and extending into the posterior mediastinum measuring: 
A, 55.6 mm on sagittal section, and B, 40.5 mm on coronal section.
Fig. 2. Histologic examination showing proliferation of parathyroid cells, 
predominantly chief cells, with a solid to follicular growth pattern and a 
thin fibrous capsule. The cells show no cytologic atypia and there was 
no evidence of invasion into the soft tissue, necrosis, fibrous bands, and 
abnormal mitoses. Hematoxylin and eosin stain.
also developed symptomatic hypocalcemia due to hungry 
bone syndrome (HBS) on the first postoperative day and 
needed aggressive intravenous calcium supplementations. 
HBS is defined as rapid, profound, and prolonged hypocal-
cemia, associated with hypophosphatemia and hypomag-
nesemia due to the abrupt withdrawal of PTH following 
parathyroidectomy in patients with severe PHPT (19). It 
has a variable incidence ranging from 13 to 87% (19-21). 
A larger volume of resected parathyroid gland, elderly, 
elevated blood urea nitrogen, elevated alkaline phosphatase 
concentrations, or low vitamin D levels and bone disease 
at the time of diagnosis are known risk factors for HBS 
(20,21). Various studies have shown the frequent occur-
rence of 25-hydroxyvitamin D deficiency among patients 
with primary hyperparathyroidism; however, only a few of 
those patients develop postoperative hypocalcemia (22). 
Among risk factors for postoperative hypocalcemia, the 
size of parathyroid adenoma has consistently been found 
to be the leading determinant of postoperative hypocalce-
mia (20,23,24). Therefore, we propose that in our case, the 
size of parathyroid adenoma was the dominant contribu-
tor to the postoperative hypocalcemia, none the less, 
25-hydroxyvitamin D deficiency further contributed to it. 
 HBS can manifest with variable symptoms ranging 
from neuromuscular irritability, perioral paresthesia to 
generalized convulsions and rarely can be fatal (19), and 
therefore, should be aggressively treated. The amount of 
calcium supplementation to treat HBS can be as high as 6 
to 12 g/day (19). Small retrospective studies have suggest-
ed the prophylactic role of preoperative bisphosphonate 
and vitamin D supplementation in preventing HBS among 
patients with PA, however, larger randomized control 
trials are lacking (25,26). Furthermore, there is no current 
evidence on the role of bisphosphonate and vitamin D 
supplementation among patients with GPAs. 
 A single center study showing lack of recurrent hyper-
calcemia following parathyroidectomy among patients with 
PA suggests a benign pathophysiology (11). Furthermore, 
studies have shown a similar incidence of recurrent and 
persistent hyperparathyroidism following parathyroidec-
tomy for PA and GPA (3). 
CONCLUSION
 GPAs are an uncommon type of PA and represents a 
distinct clinical entity with features different from both 
PA and parathyroid carcinoma and can create a diagnostic 
dilemma. The risk of postoperative hypocalcemia second-
ary to HBS, could be higher among patients with GPA 
compared to PA and hence close postoperative monitoring 
is vital. However, this hypothesis needs be validated with 
further studies. 
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